Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL202 in advanced solid tumors
NCT06107686Phase 2Recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YL202 in non-small cell lung cancer (NSCLC), breast cancer, head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC), gastric cancer (GC), sponsored by MediLink Therapeutics. Started Dec 2023; status: recruiting.
02
Drugs
YL202
03
Conditions
non-small cell lung cancer (NSCLC)breast cancerhead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06107686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107686.